ASCO
Liquid Biopsy Firms Eye Melanoma for Minimal Residual Disease Testing, Though Questions Remain
Premium
MRD assays show promise in immunotherapy response prediction with the potential to guide dose/treatment escalation with emerging adjuvant approaches.
Personalized Residual Disease Assays Show Promise to Overcome Liquid Biopsy Challenges in Sarcomas
Premium
New data presented at the ASCO annual meeting this week showed that tumor-informed assays could detect emerging recurrence ahead of imaging.
Early Adopters Share Experiences With Grail Cancer Test as Firm Faces New Clinical Questions
Premium
Real-world and trial data shored up evidence that the company's multi-cancer detection assay can guide follow-up assessment of patients with a positive result.
The 53-gene biomarker signature showed promise in predicting immunotherapy response in high-risk triple-negative and HR-positive breast cancer.
Large Study of Early-Onset Colorectal Cancer Patients IDs Unique, Potentially Actionable Mutations
In younger patients, HER2 mutations were more prevalent in those who had MSI-high/TMB-high tumors, while POLE mutations were more common in MSS/TMB-high tumors, researchers reported at ASCO.